• +1-646-491-9876
    • +91-20-67278686

    Search

    Glial Cell Line Derived Neurotrophic Factor-Pipeline Review H2 2017

    Glial Cell Line Derived Neurotrophic Factor-Pipeline Review H2 2017

    • Report Code ID: RW00011060479
    • Category Life Sciences
    • No. of Pages 47
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Pipeline Review, H2 2017

    Summary

    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor-Pipeline Review, H2 2017, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Glial-derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene. The molecules developed by companies in Phase II and Preclinical stages are 2 and 4 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Ophthalmology which include indications Amyotrophic Lateral Sclerosis, Parkinson's Disease, Brain Ischemia, Neurodegenerative Diseases and Retinal Degeneration.

    Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
    -The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Overview 6
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Therapeutics Development 7
    Products under Development by Stage of Development 7
    Products under Development by Therapy Area 8
    Products under Development by Indication 9
    Products under Development by Companies 10
    Products under Development by Universities/Institutes 12
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Therapeutics Assessment 14
    Assessment by Mechanism of Action 14
    Assessment by Route of Administration 16
    Assessment by Molecule Type 18
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Companies Involved in Therapeutics Development 20
    GlaxoSmithKline Plc 20
    Treeway BV 20
    UniQure NV 20
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Drug Profiles 22
    AMT-090-Drug Profile 22
    Product Description 22
    Mechanism Of Action 22
    R&D Progress 22
    Drugs for Neurodegenerative Diseases-Drug Profile 24
    Product Description 24
    Mechanism Of Action 24
    R&D Progress 24
    Fusion Protein to Activate GDNF for Brain Ischemia-Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    GSK-812-Drug Profile 26
    Product Description 26
    Mechanism Of Action 26
    R&D Progress 26
    LAUR-301-Drug Profile 27
    Product Description 27
    Mechanism Of Action 27
    R&D Progress 27
    smilagenin-Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis-Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    TW-002-Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Dormant Products 34
    Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)-Product Development Milestones 35
    Featured News & Press Releases 35
    Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients 35
    Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association 36
    Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy 37
    Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 37
    Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane 38
    Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 39
    Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease 40
    Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 40
    Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 41
    Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 42
    Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 43
    Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 43
    Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 44
    Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson's Disease 44
    Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 45
    Appendix 46
    Methodology 46
    Coverage 46
    Secondary Research 46
    Primary Research 46
    Expert Panel Validation 46
    Contact Us 46
    Disclaimer 47

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Indication, H2 2017 9
    Number of Products under Development by Companies, H2 2017 10
    Products under Development by Companies, H2 2017 11
    Number of Products under Investigation by Universities/Institutes, H2 2017 12
    Products under Investigation by Universities/Institutes, H2 2017 13
    Number of Products by Stage and Mechanism of Actions, H2 2017 15
    Number of Products by Stage and Route of Administration, H2 2017 17
    Number of Products by Stage and Molecule Type, H2 2017 19
    Pipeline by GlaxoSmithKline Plc, H2 2017 20
    Pipeline by Treeway BV, H2 2017 20
    Pipeline by UniQure NV, H2 2017 21
    Dormant Projects, H2 2017 34

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Top 10 Indications, H2 2017 9
    Number of Products by Mechanism of Actions, H2 2017 14
    Number of Products by Stage and Mechanism of Actions, H2 2017 14
    Number of Products by Routes of Administration, H2 2017 16
    Number of Products by Stage and Routes of Administration, H2 2017 16
    Number of Products by Molecule Types, H2 2017 18
    Number of Products by Stage and Molecule Types, H2 2017 18
    GlaxoSmithKline Plc
    Treeway BV
    UniQure NV

    Request for Sample

    Report Url https://www.reportsweb.com//glial-cell-line-derived-neurotrophic-factor-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//glial-cell-line-derived-neurotrophic-factor-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//glial-cell-line-derived-neurotrophic-factor-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments